It is still important to speak with your provider before starting any new treatment to make sure it fits your overall care plan
Data was described as median (IQR)
It states that the compounded semaglutide products provided by Noom are not approved by FDA and that they have not undergone review for safety, efficacy, or quality before being dispensed. Being clear about that limitation is the right call, and Noom does it plainly
PMID: 18703567
Back DiMarchi, R Efendic, S (1997) 'Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity', US Patent US6191102B1.Back Drucker, DJ, Habener, JF, Holst, JJ (1 Dec 2017) 'Discovery, characterization, and clinical development of the glucagon-like peptides', Journal of Clinical Investigation , 127/12, 4217-27
10.1016/j.mad.2006.11.016 Mech Ageing Dev